CUSTOM PUBLISHING

Inflammation is generally beneficial and has evolved to promote survival but can also be maladaptive when chronically activated and sustained, leading to progressive tissue injury and reduced survival, as seen in rheumatologic disease and atherosclerosis. Chronic inflammation is not a specific disease but a mechanistic process. The hallmarks of chronic inflammation are the infiltration of primary inflammatory cells such as macrophages, lymphocytes, and plasma cells in the tissue site, producing inflammatory cytokines, proteins, and growth factors that lead to the progression of tissue damage and scar tissue formation. Chronic inflammation can have deleterious effects on the body and often progresses silently, presenting a major threat to the health and longevity. Untreated chronic inflammation generally carries a poor prognosis. Disease-specific morbidity and mortality are dependent on the causative mechanistic process leading to chronic infection. The World Health Organization (WHO) ranks chronic inflammatory disease as the greatest threat to human health. Worldwide 3 of 5 people die due to chronic inflammatory diseases such as stroke, chronic respiratory diseases, heart disorders, cancer, obesity, and diabetes. It is critical for clinical researchers to identify the risk factors involved in chronic inflammation and for physicians treating different conditions including autoinflammatory diseases to recognize the insidious effects of long-term chronic inflammation, both learning from other experiences and specialties so that management of this disease can be improved and patients are approached in an holistic way.

During this webinar, the speakers will:

• Describe the molecular mechanisms of, and the current knowledge gaps in, chronic inflammation mostly in autoinflammatory diseases and what can be shared from other rheumatic diseases (lupus, rheumatoid arthritis) and specialties (cardiology, oncology)
• Discuss the impact of chronic inflammation in rheumatic diseases on various organ systems (cardiovascular, musculoskeletal, kidney, and reproductive) and why this is relevant for the subgroup of autoinflammatory diseases
• Provide information to help physicians better survey and follow patients in order to improve long-term outcomes
• Answer your questions during the live broadcast.

This webinar will last for approximately 60 minutes.

Although it is highly rewarding to create medicines, particularly therapeutic antibodies, doing so comes with several risks. It is expensive, time-consuming, and often has a high failure rate. As such, any technique that can minimize costs and time while also increasing success is considered the holy grail in biotechnology.

Coupled with advances in liquid handling, bioinformatics, and antibody expression and characterization, high-throughput surface plasmon resonance (HT-SPR) and single-cell B-cell receptor sequencing (BCR-seq) are driving the unprecedented scale, scope, and speed of biologics development. We will discuss antibody discovery by immunizing transgenic mice engineered to produce antibodies with human variable region heavy and light chains, and by using high-throughput B cell selection employing single cell sorting, Beacon®, or Nanovial Technology. These workflows maintain native pairings and output a diverse final set of binders encompassing a variety of clonotypes and heavy and light chain genes.

HT-SPR enables the evaluation of the largest of antigen–antibody interactions quickly and cost-effectively. It can also run parallel kinetic, affinity, and epitope specificity studies from the very start of the drug discovery process. scRNA-seq is a versatile tool for understanding cell types, cell states, and developmental trajectories in a diverse range of tissues and organisms. Increasingly, it is being harnessed to understand adaptive immune responses and facilitate a new paradigm of drug discovery.

During the webinar, our expert speakers will:

• Share a robust method for antigen-specific antibody identification, including current industry advances
• Help you understand cell types, cell states, and developmental workflows using BCR-seq or scRNA-seq
• Discuss how high-throughput biophysical screening, epitope binning, and mapping are allowing therapeutic candidate selection from crude samples
• Answer your questions during our live Q&A format.

This webinar will last for approximately 60 minutes.

Natural language processing (NLP) is a type of artificial intelligence (AI) that enables a computer to read, contextualize, and interpret human language. You may be familiar with this form of AI through the voice assistants that are embedded in the software of most mobile phones and that can understand instructions given in everyday speech. But NLP has many more applications beyond telling you what the weather is or playing your favorite song. It is being used to analyze electronic health records to improve patient treatment, monitor social media for hate speech or threats of violence, and filter spam emails, which can have significant economic implications for businesses and individuals. Our expert panelists will discuss these and other examples of NLP, as well as provide insights into the underlying mechanics of NLP, where it is being successfully applied, and how its continued development might provide benefits to society in the future.

During the webinar, the panelists will:

• Explain the fundamentals of NLP and the core technologies that make it work
• Delve into some representative examples of NLP applications today, including prior successes and failures
• Discuss the future of NLP technology and what challenges might lie ahead for its acceptance
• Answer your questions during the live broadcast.

This webinar will last for approximately 60 minutes.